Method Meta-analysis

Lead Research Organisation: University College London
Department Name: UNLISTED

Abstract

Systematic reviews are a way of bringing together similar clinical trials. Meta-analysis is a way of putting results or data from these trials together to work out whether treatments work, and network meta-analysis helps us decide which treatments work best.
Working alongside trial teams, we are developing new and improved ways of planning and doing these systematic reviews and meta-analyses, so that we can find out which treatments are best for patients quickly and reliably. Sometimes, treatments work better in some patients than in others, so we are also collecting more detailed data and developing reliable methods to explore this. We are developing better statistical techniques for doing all types of meta-analysis and network meta-analysis. To help others to use our new methods of doing things, we are writing user-friendly software, preparing guidance, and giving tutorials and training courses.

Technical Summary

Systematic review and meta-analysis are essential tools for rigorously evaluating the effects of therapies, particularly integrating our trial results with those of other groups, and informing the design of our trials. This programme develops the methodology underpinning systematic reviews and meta-analyses, applies it in high-quality reviews relevant to our trials, and disseminates it to the scientific community. Interaction between systematic reviewers, methodologists and trialists is fundamental to these endeavours.
We have particular experience and an international reputation in the conduct of large collaborative systematic reviews and meta-analyses based individual participant data (IPD). Over more than 20 years, these have influenced the treatment of patients globally, and moreover, the data have been used to investigate methodological issues and develop robust solutions. However, such IPD meta-analyses are time- and resource-intensive, so a key aim is to establish when they are most needed to answer clinical questions reliably. Conversely, if aggregate data approaches are to provide a robust and speedier alternative, we need to move beyond the current methods of doing these, in order to limit the inherent biases.
With some clinical areas moving rapidly, there can be multiple trials comparing different treatments to one or more standard. This means that there is sometimes little opportunity for direct comparisons, so we also need the most robust and timely methods for network meta-analysis. We refer to pairwise meta-analysis (directly comparing two treatments) as MA and network meta-analysis (directly and indirectly comparing many treatments) as NMA.
In this area, we benefit from the arrival of new senior staff in 2017, which has substantially broadened our expertise in statistical modelling for MA and NMA. Our future plans will continue to integrate this expertise into our ongoing programme of work. For example, we will develop and implement state-of-the-art methodology in MA and NMA of time-to-event outcomes based on individual participant data (IPD), informing overall and stratified treatment decisions, while allowing for complexities in the design of the component trials, heterogeneity between trials, and inconsistency between direct and indirect evidence.
Our overall philosophy is to use the simplest methods that can be shown to be valid (often by methodological comparison with more complex methods), and wherever possible to work prospectively and collaboratively to reduce bias, increase the timeliness of our reviews, and achieve greater impact.
Our research covers four priority areas:
1. Beyond standard systematic reviews – developing review methods that move beyond standard approaches and using them to perform high-quality and challenging reviews
2. Determining methods to assess which participants benefit most from treatments in pairwise and network meta-analysis
3. Choosing and building appropriate models for in pairwise and network meta-analysis
4. Guidance and tools to increase impact of our meta-analysis methods

Organisations

Publications

10 25 50

publication icon
Al Wattar B (2023) Effectiveness of treatment options for tubal ectopic pregnancy: A systematic review and network meta-analysis in BJOG: An International Journal of Obstetrics & Gynaecology

Related Projects

Project Reference Relationship Related To Start End Award Value
MC_UU_00004/01 31/03/2021 30/03/2026 £5,186,000
MC_UU_00004/02 Transfer MC_UU_00004/01 31/03/2021 30/03/2026 £4,446,000
MC_UU_00004/03 Transfer MC_UU_00004/02 31/03/2021 30/03/2026 £4,999,000
MC_UU_00004/04 Transfer MC_UU_00004/03 31/03/2021 30/03/2026 £5,315,000
MC_UU_00004/05 Transfer MC_UU_00004/04 31/03/2021 30/03/2026 £3,107,000
MC_UU_00004/06 Transfer MC_UU_00004/05 31/03/2021 30/03/2026 £2,889,000
MC_UU_00004/07 Transfer MC_UU_00004/06 31/03/2021 30/03/2026 £2,369,000
MC_UU_00004/08 Transfer MC_UU_00004/07 31/03/2021 30/03/2026 £2,270,000
MC_UU_00004/09 Transfer MC_UU_00004/08 31/03/2021 30/03/2026 £2,160,000
 
Guideline Title Covid Guidelines India
Description Anti-IL6 COVID-19 SR (PMID:34228774) CMGIG guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
Description Anti-IL6 COVID-19 SR (PMID:34228774) ERS guideline 2022
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title IDSA Guidelines on the Treatment and Management of Patients with COVID-19
Description Anti-IL6 COVID-19 SR (PMID:34228774) IDSA guideline 2022
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Interim Clinical Commissioning Policy: IL-6 inhibitors (tocilizumab or sarilumab) for hospitalised patients with COVID-19 (adults)
Description Anti-IL6 COVID-19 SR (PMID:34228774) NHS guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Therapeutics and COVID-19: Living Guideline. 6 July 2021
Description Anti-IL6 COVID-19 SR (PMID:34228774) WHO guideline 2021
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Therapeutics and COVID-19: Living Guideline. 18 August 2023
Description Anti-IL6 COVID-19 SR (PMID:34228774) WHO guideline 2023
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic
Description Bladder Adj CT IPD (PMID:15939530) EAU guideline 2021
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
URL https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/
 
Guideline Title EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic Bladder cancer
Description Bladder Adj CT IPD (PMID:15939530) EAU guideline 2022
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - v.6.2021 Bladder Cancer
Description Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2021
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - v.3.2022 Bladder Cancer
Description Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - v.1.2024 Bladder Cancer
Description Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2024
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical Practice Guideline GU-013 Version 8 (Muscle Invasive Bladder Cancer) (2021)
Description Bladder Adj CT IPD (PMID:16625650) AHS guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic Bladder cancer
Description Bladder Adj CT IPD 2005 (PMID:15939530) EAU guideline 2023
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic (2021)
Description Bladder Neo CT IPD (PMID: 15939524) EAU guideline 2021
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
URL https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/
 
Guideline Title EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic (2022)
Description Bladder Neo CT IPD (PMID: 15939524) EAU guideline 2022
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
Description Bladder Neo CT IPD (PMID: 15939524) ESMO guideline 2021
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
URL https://www.esmo.org/guidelines/genitourinary-cancers/bladder-cancer
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 6.2021
Description Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2021
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 3.2022
Description Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 1.2024
Description Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2024
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical Practice Guideline GU-013 Version 6 (Muscle Invasive Bladder Cancer) (2021)
Description Bladder Neo CT IPD (PMID:15846746) AHS Guideline 2021
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical Practice Guideline GU-013 Version 8 (Muscle Invasive Bladder Cancer) (2023)
Description Bladder Neo CT IPD (PMID:15939524) AHS Guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.1 2021
Description Cervix CTRT IPD (PMID: 19001332) GGPO guideline 2021
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
URL https://www.awmf.org/uploads/tx_szleitlinien/032-033OLl_S3_Diagnostik_Therapie_Nachsorge_Zervixkarzi...
 
Guideline Title S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.1 2021
Description Cervix CTRT IPD (PMID: 19001332) GGPO guideline 2021
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
URL https://www.awmf.org/uploads/tx_szleitlinien/032-033OLl_S3_Diagnostik_Therapie_Nachsorge_Zervixkarzi...
 
Guideline Title S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.2 2022
Description Cervix CTRT IPD (PMID: 19001332) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2022 Cervical Cancer
Description Cervix CTRT IPD (PMID:19001332) NCCN guideline 2022 (1)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2023 Cervical Cancer
Description Cervix CTRT IPD (PMID:19001332) NCCN guideline 2023 (1)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1 2024 Cervical Cancer
Description Cervix CTRT IPD (PMID:19001332) NCCN guideline 2024 (1)
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2022 Cervical Cancer
Description Cervix CTRT IPD (PMID:20091632) NCCN guideline 2022 (1)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2023 Cervical Cancer
Description Cervix CTRT IPD (PMID:20091632) NCCN guideline 2023 (1)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2024 Cervical Cancer
Description Cervix CTRT IPD (PMID:20091632) NCCN guideline 2024 (1)
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.2 2022
Description Cervix CTRT SR (PMID: 16034873) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update
Description Cervix Neo CT IPD (PMID: 15106161) ASCO guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Cancer of the Uterine Cervix
Description Cervix Neo CT SR (PMID:23235641) AHS guideline 2021
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
URL https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gyne004-cervical.pdf
 
Guideline Title Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update
Description Cervix Neo CT SR (PMID:23235641) ASCO guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.1 2021
Description Cervix Neo CT SR (PMID:23235641) GGPO guideline 2021
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
URL https://www.awmf.org/uploads/tx_szleitlinien/032-033OLl_S3_Diagnostik_Therapie_Nachsorge_Zervixkarzi...
 
Guideline Title S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.2 2022
Description Cervix Neo CT SR (PMID:23235641) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title S3-Leitlinie endometrriumkarzinom V2.0 (2022)
Description Endometrial CT SR (PMID: 22895938) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title S3-Leitlinie endometrriumkarzinom V3.01 (2023)
Description Endometrial CT SR (PMID: 22895938) GGPO guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1 2022. Uterine Neoplasms
Description Endometrial CT SR (PMID:17150999) NCCN guideline 2022 (V1)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1 2024. Uterine Neoplasms
Description Endometrial CT SR (PMID:17150999) NCCN guideline 2024 (V1)
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1.2022. Non-Small Cell Lung Cancer
Description Lung Adj CT IPD (PMID:20338628) NCCN guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer
Description Lung Adj CT IPD (PMID:20338628) NCCN guideline 2023
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.2.2024. Non-Small Cell Lung Cancer
Description Lung Adj CT IPD (PMID:20338628) NCCN guideline 2024
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
Description Lung Adj CT IPD (PMID:25730344) ASCO guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
Description Lung CT 95 IPD (PMID:7580546) ASCO guideline stage I-III NSCLC 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative
Description Lung CT 95 IPD (PMID:7580546) CSCO-ESMO guideline 2018
Geographic Reach Asia 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1.2022. Non-Small Cell Lung Cancer
Description Lung CT 95 IPD (PMID:7580546) NCCN guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Lung CT 95 IPD (PMID:7580546) NCCN guideline 2023
Description Lung CT 95 IPD (PMID:7580546) NCCN guideline 2023
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022)
Description Lung Neo CT IPD (PMID: 24576776) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V3.01 (2023)
Description Lung Neo CT IPD (PMID: 24576776) GGPO guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1.2022. Non-Small Cell Lung Cancer
Description Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer
Description Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2023
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022)
Description Lung PORT IPD (PMID: 9690404) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V3.01 (2023)
Description Lung PORT IPD (PMID: 9690404) GGPO guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1.2022. Non-Small Cell Lung Cancer
Description Lung PORT IPD (PMID: 9690404) NCCN guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer
Description Lung PORT IPD (PMID: 9690404) NCCN guideline 2023
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.2.2024. Non-Small Cell Lung Cancer
Description Lung PORT IPD (PMID: 9690404) NCCN guideline 2024
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
Description Lung PORT IPD (PMID: 9690404; 23453644) ASCO guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022)
Description Lung SC IPD (PMID: 18678835) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V3.01 (2024)
Description Lung SC IPD (PMID: 18678835) GGPO guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1.2022. Non-Small Cell Lung Cancer
Description Lung SC IPD (PMID: 18678835) NCCN guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer
Description Lung SC IPD (PMID: 18678835) NCCN guideline 2023
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022)
Description Lung SC IPD (PMID: 25730344) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V3.01 (2023)
Description Lung SC IPD (PMID: 25730344) GGPO guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative
Description Lung SC IPD (PMID:18678835) CSCO-ESMO guideline 2018
Geographic Reach Asia 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022)
Description Lung SeqCon CTRT IPD (PMID:20351327) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V3.01 (2023)
Description Lung SeqCon CTRT IPD (PMID:20351327) GGPO guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v1.2022. Non-Small Cell Lung Cancer
Description Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v1.2023. Non-Small Cell Lung Cancer
Description Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2023
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v2.2024. Non-Small Cell Lung Cancer
Description Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2024
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Leitlinienprogramm onkologie. Diagnostik und therapie des Ösophaguskarzinoms v3.0 2021
Description Oesophagus RT IPD (PMID:16235286) GGPO guideline 2021
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
URL https://www.leitlinienprogramm-onkologie.de/leitlinien/oesophaguskarzinom/
 
Guideline Title Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. V3.1 (2022)
Description Oesophagus RT IPD (PMID:16235286) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. V4.0 (2023)
Description Oesophagus RT IPD (PMID:16235286) GGPO guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Guidelines Version 1.2022 Esophageal and Esophagogastric Junction Cancers
Description Oesophagus RT IPD (PMID:9635705) NCCN guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Guidelines Version 5.2022 Esophageal and Esophagogastric Junction Cancers
Description Oesophagus RT IPD (PMID:9635705) NCCN guideline 2022 (v5)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Guidelines Version 4.2023 Esophageal and Esophagogastric Junction Cancers
Description Oesophagus RT IPD (PMID:9635705) NCCN guideline 2023 (v4)
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2021)
Description Prostate Abi AD (PMID: 28800492) EAU guideline 2021
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2022)
Description Prostate Abi AD (PMID: 28800492) EAU guideline 2022
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2023)
Description Prostate Abi AD (PMID: 28800492) EAU guideline 2023
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Local Prostate Cancer
Description Prostate Artistic AD (PMID: 33002431) AHS guideline 2021
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
URL https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gu012-local-prostate.p...
 
Guideline Title Local Prostate Cancer
Description Prostate Artistic AD (PMID: 33002431) AHS guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinically Localized Prostate Cancer: AUA/ASTRO Guideline (2022)
Description Prostate Artistic AD (PMID: 33002431) AUA/ASTRO guideline 2022
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2021)
Description Prostate Artistic AD (PMID: 33002431) EAU guideline 2021
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
URL https://uroweb.org/guideline/prostate-cancer/
 
Guideline Title EAU Guideline: Prostate Cancer (2022)
Description Prostate Artistic AD (PMID: 33002431) EAU guideline 2022
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2023)
Description Prostate Artistic AD (PMID: 33002431) EAU guideline 2023
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Leitlinie Prostatakarzinom v6.2 2021
Description Prostate Artistic AD (PMID: 33002431) GGPO guideline 2021
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
URL https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/
 
Guideline Title NCCN Practice Guidelines in Oncology - v.2.2022 Prostate Cancer
Description Prostate Artistic AD (PMID: 33002431) NCCN guideline 2021 V2
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2023 Prostate Cancer
Description Prostate Artistic AD (PMID: 33002431) NCCN guideline 2023 V1
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.4.2023 Prostate Cancer
Description Prostate Artistic AD (PMID: 33002431) NCCN guideline 2023 V4
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Pan-Asian adapted ESMO Guidelines (2022)
Description Prostate Artistic AD (PMID: 33002431) PAGA ESMO guideline 2022
Geographic Reach Asia 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2022)
Description Prostate CT SR (PMID: 26718929) EAU guideline 2022
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2023)
Description Prostate CT SR (PMID: 26718929) EAU guideline 2023
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Leitlinie Prostatakarzinom v6.2 2021
Description Prostate CT SR (PMID: 26718929) GGPO guideline 2021
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
URL https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/
 
Guideline Title NCCN Practice Guidelines in Oncology - v.2.2022 Prostate Cancer
Description Prostate CT SR (PMID: 26718929) NCCN guideline 2021 V2
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2023 Prostate Cancer
Description Prostate CT SR (PMID: 26718929) NCCN guideline 2023
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Pan-Asian adapted ESMO Guidelines (2022)
Description Prostate CT SR (PMID: 26718929) PAGA ESMO guideline 2022
Geographic Reach Asia 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2023 Prostate Cancer
Description Prostate CT SR (PMID: 30826218) NCCN guideline 2023
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.4.2023 Prostate Cancer
Description Prostate CT SR (PMID: 30826218) NCCN guideline 2023 v4
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2021)
Description Prostate Network AD (PMID: 29788164) EAU guideline 2021
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
URL https://uroweb.org/guideline/prostate-cancer/
 
Guideline Title EAU Guideline: Prostate Cancer (2022)
Description Prostate Network AD (PMID: 29788164) EAU guideline 2022
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title 2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer
Description Prostate RT AD (PMID: 30826218) CUA guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2021)
Description Prostate RT AD (PMID: 30826218) EAU guideline 2021
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
URL https://uroweb.org/guideline/prostate-cancer/
 
Guideline Title EAU Guideline: Prostate Cancer (2022)
Description Prostate RT AD (PMID: 30826218) EAU guideline 2022
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2023)
Description Prostate RT AD (PMID: 30826218) EAU guideline 2023
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Leitlinie Prostatakarzinom v6.2 2021
Description Prostate RT AD (PMID: 30826218) GGPO guideline 2021
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
URL https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v2.2022 Soft Tissue Sarcoma
Description Sarcoma CT IPD (PMID:9400508) NCCN guideline 2021 (V2)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v3.2023 Soft Tissue Sarcoma
Description Sarcoma CT IPD (PMID:9400508) NCCN guideline 2023 (V3)
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v.2.2021 Soft Tissue Sarcoma
Description Sarcoma CT SR (PMID:7640234) NCCN guideline 2021 (V2)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v.2.2022 Soft Tissue Sarcoma
Description Sarcoma CT SR (PMID:7640234) NCCN guideline 2022 (V2)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v.3.2023 Soft Tissue Sarcoma
Description Sarcoma CT SR (PMID:7640234) NCCN guideline 2023 (V3)
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Description NIHR Development and Skills Enhancement Award
Amount £34,926 (GBP)
Funding ID NIHR301653 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 03/2021 
End 03/2022
 
Description TMRP Doctoral Training Programme
Amount £2,518,806 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 08/2021 
End 09/2026
 
Description Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials 
Organisation Circolo Hospital and Macchi Foundation
Country Italy 
Sector Hospitals 
PI Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision
Collaborator Contribution Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision
Impact 1 protocol, and 1 paper (PMID: 34802798)
Start Year 2017
 
Description Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials 
Organisation European Organisation for Research and Treatment of Cancer (EORTC)
Country Belgium 
Sector Charity/Non Profit 
PI Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision
Collaborator Contribution Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision
Impact 1 protocol, and 1 paper (PMID: 34802798)
Start Year 2017
 
Description Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials 
Organisation N.N. Alexandrov National Cancer Centre of Belarus
Country Belarus 
Sector Private 
PI Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision
Collaborator Contribution Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision
Impact 1 protocol, and 1 paper (PMID: 34802798)
Start Year 2017
 
Description Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials 
Organisation NewYork-Presbyterian Hospital
Country United States 
Sector Hospitals 
PI Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision
Collaborator Contribution Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision
Impact 1 protocol, and 1 paper (PMID: 34802798)
Start Year 2017
 
Description Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials 
Organisation Saarland University
Country Germany 
Sector Academic/University 
PI Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision
Collaborator Contribution Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision
Impact 1 protocol, and 1 paper (PMID: 34802798)
Start Year 2017
 
Description Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials 
Organisation Saint Louis University
Country United States 
Sector Academic/University 
PI Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision
Collaborator Contribution Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision
Impact 1 protocol, and 1 paper (PMID: 34802798)
Start Year 2017
 
Description Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials 
Organisation Sapienza University of Rome
Country Italy 
Sector Academic/University 
PI Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision
Collaborator Contribution Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision
Impact 1 protocol, and 1 paper (PMID: 34802798)
Start Year 2017
 
Description Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials 
Organisation The Christie NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision
Collaborator Contribution Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision
Impact 1 protocol, and 1 paper (PMID: 34802798)
Start Year 2017
 
Description Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials 
Organisation University Hospital Erlangen
Country Germany 
Sector Hospitals 
PI Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision
Collaborator Contribution Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision
Impact 1 protocol, and 1 paper (PMID: 34802798)
Start Year 2017
 
Description Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials 
Organisation University of Bern
Country Switzerland 
Sector Academic/University 
PI Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision
Collaborator Contribution Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision
Impact 1 protocol, and 1 paper (PMID: 34802798)
Start Year 2017
 
Description Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials 
Organisation University of Connecticut
Country United States 
Sector Academic/University 
PI Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision
Collaborator Contribution Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision
Impact 1 protocol, and 1 paper (PMID: 34802798)
Start Year 2017
 
Description Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials 
Organisation University of Kiel
Country Germany 
Sector Academic/University 
PI Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision
Collaborator Contribution Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision
Impact 1 protocol, and 1 paper (PMID: 34802798)
Start Year 2017
 
Description Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials 
Organisation University of Southern California
Country United States 
Sector Academic/University 
PI Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; supervision
Collaborator Contribution Study concept and design; provision of IPD; critical revision of the manuscript for important intellectual content and supervision
Impact 1 protocol, and 1 paper (PMID: 34802798)
Start Year 2017
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation Antwerp University Hospital
Country Belgium 
Sector Hospitals 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation Cantonal Hospital St. Gallen
Country Switzerland 
Sector Hospitals 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation Leiden University Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation National Cancer Centre Singapore
Country Singapore 
Sector Hospitals 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation Oslo University Hospital
Country Norway 
Sector Hospitals 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation Saitama Medical University
Country Japan 
Sector Academic/University 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation Swiss Group for Cancer Clinical Research (SAKK)
Country Switzerland 
Sector Academic/University 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation Tata Memorial Hospital
Country India 
Sector Hospitals 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation University of Bern
Country Switzerland 
Sector Academic/University 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation University of Sydney
Department NHMRC Clinical Trials Centre
Country Australia 
Sector Academic/University 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Albert Schweitzer Hospital
Country Netherlands 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Ann Arbor VA Medical Center
Country United States 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Beneficência Portuguesa de São Paulo
Country Brazil 
Sector Charity/Non Profit 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Berry Consultants LLC
Country United States 
Sector Private 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Genentech, Inc
Country United States 
Sector Private 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Ghent University Hospital
Country Belgium 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Guy's and St Thomas' NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Health Data Research UK
Country United Kingdom 
Sector Private 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Hebrew University of Jerusalem
Department Hebrew University Hadassah Medical School
Country Israel 
Sector Academic/University 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Hospital Ramón y Cajal
Country Spain 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Hospital Reina Sofía de Córdoba
Country Spain 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Hospital Universitario Puerta de Hierro
Country Spain 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Hospital de Sant Pau
Country Spain 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Karolinska University Hospital
Country Sweden 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Massachusetts General Hospital
Country United States 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Massachusetts General Hospital
Country United States 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Ministry of Health
Country Malaysia 
Sector Public 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation National Institute of Health and Medical Research (INSERM)
Department INSERM U1153 (Center for Epidemiology and Biostatistics)
Country France 
Sector Academic/University 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Necker-Enfants Malades Hospital
Country France 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Public Assistance - Hospitals of Paris
Country France 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Queen's Medical Center
Country United States 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Regeneron Pharmaceuticals, Inc.
Country United States 
Sector Private 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Sanofi
Department Genzyme Corporation
Country United States 
Sector Private 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation Turku University Hospital
Country Finland 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation University Hospital La Princesa
Country Spain 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation University Hospital of Valme
Country Spain 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation University Hospitals Bristol and Weston NHS Foundation Trust
Country United Kingdom 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation University Medical Center Utrecht (UMC)
Country Netherlands 
Sector Academic/University 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation University of Bristol
Country United Kingdom 
Sector Academic/University 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation University of British Columbia
Country Canada 
Sector Academic/University 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation University of Chicago Medical Center
Country United States 
Sector Hospitals 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation University of Groningen
Country Netherlands 
Sector Academic/University 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation University of Malaya
Country Malaysia 
Sector Academic/University 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation University of Melbourne
Country Australia 
Sector Academic/University 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation University of Oxford
Department Nuffield Department of Population Health
Country United Kingdom 
Sector Academic/University 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation University of Paris
Country France 
Sector Academic/University 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation University of Toronto
Country Canada 
Sector Academic/University 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Organisation World Health Organization (WHO)
Country Global 
Sector Public 
PI Contribution Concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript and critical revision of the manuscript
Collaborator Contribution Obtained funding, concept and design, acquisition, analysis, or interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript, administrative, technical, or material support and supervision
Impact 1 protocol, and 1 paper (PMID: 35076012), 1 guideline
Start Year 2021
 
Description Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review 
Organisation Barts Health NHS Trust
Country United Kingdom 
Sector Public 
PI Contribution Design of the review; advised on methodology and contributed to and approved the final manuscript
Collaborator Contribution Design of the review; wrote the protocol; undertook literature review and analysis; devised the strategies for database searches and contributed to and approved the final manuscript
Impact 1 protocol, and 1 paper (PMID: 34404753)
Start Year 2018
 
Description Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Design of the review; advised on methodology and contributed to and approved the final manuscript
Collaborator Contribution Design of the review; wrote the protocol; undertook literature review and analysis; devised the strategies for database searches and contributed to and approved the final manuscript
Impact 1 protocol, and 1 paper (PMID: 34404753)
Start Year 2018
 
Description Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review 
Organisation Queen Mary University of London
Country United Kingdom 
Sector Academic/University 
PI Contribution Design of the review; advised on methodology and contributed to and approved the final manuscript
Collaborator Contribution Design of the review; wrote the protocol; undertook literature review and analysis; devised the strategies for database searches and contributed to and approved the final manuscript
Impact 1 protocol, and 1 paper (PMID: 34404753)
Start Year 2018
 
Description Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review 
Organisation University College London
Department Lungs for Living Research Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution Design of the review; advised on methodology and contributed to and approved the final manuscript
Collaborator Contribution Design of the review; wrote the protocol; undertook literature review and analysis; devised the strategies for database searches and contributed to and approved the final manuscript
Impact 1 protocol, and 1 paper (PMID: 34404753)
Start Year 2018
 
Description Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review 
Organisation University of Leicester
Department Respiratory Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Design of the review; advised on methodology and contributed to and approved the final manuscript
Collaborator Contribution Design of the review; wrote the protocol; undertook literature review and analysis; devised the strategies for database searches and contributed to and approved the final manuscript
Impact 1 protocol, and 1 paper (PMID: 34404753)
Start Year 2018
 
Description Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation 
Organisation Pumping Marvellous Foundation
Country United Kingdom 
Sector Private 
PI Contribution Member of the Project Advisory Group, provided feedback and advice during the project, and commented on the final report.
Collaborator Contribution Development of the protocol, economic analysis and the statistical analysis plan. Performed all database searches, provided oversight of data extraction and quality assessment the analyses, provided data and information about the data and contributed to the writing of all sections of the report
Impact 1 protocol, and 1 paper (PMID: 35076012)
Start Year 2018
 
Description Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation 
Organisation Somerset NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Member of the Project Advisory Group, provided feedback and advice during the project, and commented on the final report.
Collaborator Contribution Development of the protocol, economic analysis and the statistical analysis plan. Performed all database searches, provided oversight of data extraction and quality assessment the analyses, provided data and information about the data and contributed to the writing of all sections of the report
Impact 1 protocol, and 1 paper (PMID: 35076012)
Start Year 2018
 
Description Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation 
Organisation University of Leeds
Department Leeds School of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Member of the Project Advisory Group, provided feedback and advice during the project, and commented on the final report.
Collaborator Contribution Development of the protocol, economic analysis and the statistical analysis plan. Performed all database searches, provided oversight of data extraction and quality assessment the analyses, provided data and information about the data and contributed to the writing of all sections of the report
Impact 1 protocol, and 1 paper (PMID: 35076012)
Start Year 2018
 
Description Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation 
Organisation University of Maryland
Department School of Medicine Maryland
Country United States 
Sector Academic/University 
PI Contribution Member of the Project Advisory Group, provided feedback and advice during the project, and commented on the final report.
Collaborator Contribution Development of the protocol, economic analysis and the statistical analysis plan. Performed all database searches, provided oversight of data extraction and quality assessment the analyses, provided data and information about the data and contributed to the writing of all sections of the report
Impact 1 protocol, and 1 paper (PMID: 35076012)
Start Year 2018
 
Description Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation 
Organisation University of York
Department Centre for Reviews and Dissemination (CRD)
Country United Kingdom 
Sector Academic/University 
PI Contribution Member of the Project Advisory Group, provided feedback and advice during the project, and commented on the final report.
Collaborator Contribution Development of the protocol, economic analysis and the statistical analysis plan. Performed all database searches, provided oversight of data extraction and quality assessment the analyses, provided data and information about the data and contributed to the writing of all sections of the report
Impact 1 protocol, and 1 paper (PMID: 35076012)
Start Year 2018
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation Akershus University Hospital
Country Norway 
Sector Hospitals 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation Albert Schweitzer Hospital
Country Netherlands 
Sector Hospitals 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation Cornell University
Department Weill Cornell Medicine
Country United States 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation Fudan University
Country China 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation George Institute for Global Health
Country Australia 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation McMaster University
Country Canada 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation Peking University
Country China 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation Radboud University Nijmegen Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation Umea University
Country Sweden 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation University of British Columbia
Country Canada 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation University of Copenhagen
Country Denmark 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation University of Côte d'Azur
Country France 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation University of Lille
Country France 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation University of Twente
Country Netherlands 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation University of Western Australia
Country Australia 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation University of Wurzburg
Country Germany 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Collaboration Of Controlled Randomised trials of long-term Oral Antithrombotic agents after spontaneous intraCranial Haemorrhage (COCROACH): Individual Participant Data Meta-Analysis 
Organisation Yale University
Department School of Medicine
Country United States 
Sector Academic/University 
PI Contribution Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact 1 protocol and 1 SAP
Start Year 2017
 
Description Dealing with Missing Data in an IPD Meta-analysis (Chapter 18). In: Individual participant data meta-analysis: A handbook for healthcare research 
Organisation Maastricht University (UM)
Country Netherlands 
Sector Academic/University 
PI Contribution Co-authored the chapter
Collaborator Contribution Co-authored the chapter. One partner led writing the chapter and one was co-editor of book
Impact 1 book chapter (Chapter 18)
Start Year 2015
 
Description Dealing with Missing Data in an IPD Meta-analysis (Chapter 18). In: Individual participant data meta-analysis: A handbook for healthcare research 
Organisation University Medical Center Utrecht (UMC)
Country Netherlands 
Sector Academic/University 
PI Contribution Co-authored the chapter
Collaborator Contribution Co-authored the chapter. One partner led writing the chapter and one was co-editor of book
Impact 1 book chapter (Chapter 18)
Start Year 2015
 
Description Development of a checklist of standard items for processing individual participant data from randomised trials for meta-analyses: protocol for a modified e-Delphi study 
Organisation Deakin University
Country Australia 
Sector Academic/University 
PI Contribution Members of the research team contributed to the design of the protocol, commented on drafts and advised on the scoping review
Collaborator Contribution Conceptualised design of study, gained funding, developed and drafted protocol. Carried out scoping review
Impact 1 protocol, and 1 paper (PMID: 36219622)
Start Year 2021
 
Description Development of a checklist of standard items for processing individual participant data from randomised trials for meta-analyses: protocol for a modified e-Delphi study 
Organisation Monash University
Country Australia 
Sector Academic/University 
PI Contribution Members of the research team contributed to the design of the protocol, commented on drafts and advised on the scoping review
Collaborator Contribution Conceptualised design of study, gained funding, developed and drafted protocol. Carried out scoping review
Impact 1 protocol, and 1 paper (PMID: 36219622)
Start Year 2021
 
Description Development of a checklist of standard items for processing individual participant data from randomised trials for meta-analyses: protocol for a modified e-Delphi study 
Organisation Queen's University Belfast
Country United Kingdom 
Sector Academic/University 
PI Contribution Members of the research team contributed to the design of the protocol, commented on drafts and advised on the scoping review
Collaborator Contribution Conceptualised design of study, gained funding, developed and drafted protocol. Carried out scoping review
Impact 1 protocol, and 1 paper (PMID: 36219622)
Start Year 2021
 
Description Development of a checklist of standard items for processing individual participant data from randomised trials for meta-analyses: protocol for a modified e-Delphi study 
Organisation University of Sydney
Department NHMRC Clinical Trials Centre
Country Australia 
Sector Academic/University 
PI Contribution Members of the research team contributed to the design of the protocol, commented on drafts and advised on the scoping review
Collaborator Contribution Conceptualised design of study, gained funding, developed and drafted protocol. Carried out scoping review
Impact 1 protocol, and 1 paper (PMID: 36219622)
Start Year 2021
 
Description Efficacy and moderators of efficacy of trauma-focused cognitive behavioural therapies in children and adolescents: protocol for an individual participant data meta-analysis from randomised trials 
Organisation Cambridgeshire and Peterborough NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Contributed to study methods; critically reviewed and approved the final manuscript
Collaborator Contribution Designed the project; critically reviewed and approved the final manuscript.
Impact Protocol - PROSPERO CRD42019151954 Publication of Protocol - doi: 10.1136/bmjopen-2020-047212
Start Year 2020
 
Description Efficacy and moderators of efficacy of trauma-focused cognitive behavioural therapies in children and adolescents: protocol for an individual participant data meta-analysis from randomised trials 
Organisation University Children's Hospital Zurich
Country Switzerland 
Sector Hospitals 
PI Contribution Contributed to study methods; critically reviewed and approved the final manuscript
Collaborator Contribution Designed the project; critically reviewed and approved the final manuscript.
Impact Protocol - PROSPERO CRD42019151954 Publication of Protocol - doi: 10.1136/bmjopen-2020-047212
Start Year 2020
 
Description Efficacy and moderators of efficacy of trauma-focused cognitive behavioural therapies in children and adolescents: protocol for an individual participant data meta-analysis from randomised trials 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to study methods; critically reviewed and approved the final manuscript
Collaborator Contribution Designed the project; critically reviewed and approved the final manuscript.
Impact Protocol - PROSPERO CRD42019151954 Publication of Protocol - doi: 10.1136/bmjopen-2020-047212
Start Year 2020
 
Description Efficacy and moderators of efficacy of trauma-focused cognitive behavioural therapies in children and adolescents: protocol for an individual participant data meta-analysis from randomised trials 
Organisation University of East Anglia
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to study methods; critically reviewed and approved the final manuscript
Collaborator Contribution Designed the project; critically reviewed and approved the final manuscript.
Impact Protocol - PROSPERO CRD42019151954 Publication of Protocol - doi: 10.1136/bmjopen-2020-047212
Start Year 2020
 
Description Efficacy and moderators of efficacy of trauma-focused cognitive behavioural therapies in children and adolescents: protocol for an individual participant data meta-analysis from randomised trials 
Organisation University of Zurich
Country Switzerland 
Sector Academic/University 
PI Contribution Contributed to study methods; critically reviewed and approved the final manuscript
Collaborator Contribution Designed the project; critically reviewed and approved the final manuscript.
Impact Protocol - PROSPERO CRD42019151954 Publication of Protocol - doi: 10.1136/bmjopen-2020-047212
Start Year 2020
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation Australian Institute of Family Studies
Country Australia 
Sector Public 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation Baylor College of Medicine
Country United States 
Sector Hospitals 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation California Pacific Medical Center
Country United States 
Sector Hospitals 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation Catholic University of Louvain
Country Belgium 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation Fiona Stanley Hospital
Country Australia 
Sector Hospitals 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation Flinders University
Country Australia 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation Harvard University
Department Harvard Medical School
Country United States 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation Johns Hopkins University
Country United States 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation Monash University
Country Australia 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation Oregon Health and Science University
Country United States 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation Sahlgrenska University Hospital
Country Sweden 
Sector Hospitals 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation Skåne University Hospital
Country Sweden 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation University of Adelaide
Country Australia 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation University of California, San Francisco
Country United States 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation University of Gothenburg
Country Sweden 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation University of Greifswald
Country Germany 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation University of New South Wales
Country Australia 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation University of North Carolina at Chapel Hill
Country United States 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation University of Sydney
Country Australia 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation University of Washington
Country United States 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description Factors associated with circulating sex hormones in men : individual participant data meta-analyses 
Organisation University of Western Australia
Country Australia 
Sector Academic/University 
PI Contribution Analysis and interpretation of the data; Statistical expertise; Final approval of the article
Collaborator Contribution Conception and design; Analysis and interpretation of the data; Drafting of the article; Critical revision for important intellectual content; Final approval of the article; Provision of study materials or patients; Statistical expertise; Obtaining of funding; Administrative, technical, or logistic support; Collection and assembly of data.
Impact Protocol: PROSPERO CRD42019139668 Publication: https://doi.org/10.7326/M23-0342
Start Year 2021
 
Description IW advisor to Orestis Efthimiou grant 
Organisation University of Bern
Country Switzerland 
Sector Academic/University 
PI Contribution Advised on development and submission of successful research grant proposal to Swiss National Science Foundation (SNSF). Collaborated on two papers.
Collaborator Contribution Developed and submitted successful research grant proposal to Swiss National Science Foundation (SNSF). Collaborated on two papers.
Impact Two papers published so far.
Start Year 2017
 
Description IW collaborator on SNSF grant, PI Georgia Salanti 
Organisation University of Bern
Country Switzerland 
Sector Academic/University 
PI Contribution Advised on development and submission of successful grant application to SNF. Collaborating on papers.
Collaborator Contribution Developed and submitted successful grant application to SNF. Collaborating on papers.
Impact Multi-disciplinary - epidemiology, systematic review, biostatistics. One publication on treatment hierarchy question. Future impact on conduct of network meta-analysis.
Start Year 2017
 
Description IW in ROBIS-NMA group 
Organisation University of Bristol
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed expertise in network meta-analysis
Collaborator Contribution Contributed expertise in systematic review and network meta-analysis
Impact Multidisciplinary work - systematic review and biostatistics. Current outputs - two publications on methods for developing the tool. Future outputs - tool for evaluating risk of bias in a network meta-analysis, expected impact on use of network meta-analysis in health policy making
Start Year 2020
 
Description IW in ROBIS-NMA group 
Organisation University of Toronto
Country Canada 
Sector Academic/University 
PI Contribution Contributed expertise in network meta-analysis
Collaborator Contribution Contributed expertise in systematic review and network meta-analysis
Impact Multidisciplinary work - systematic review and biostatistics. Current outputs - two publications on methods for developing the tool. Future outputs - tool for evaluating risk of bias in a network meta-analysis, expected impact on use of network meta-analysis in health policy making
Start Year 2020
 
Description Incorporating dose effects in network meta-analysis 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Contributed to the conception and design of this study, and to the manuscript's revision and interpretation of findings
Collaborator Contribution Conceived the study idea, contributed to the study design, developed model codes, prepared datasets, completed analyses, contributed to interpretation of findings, drafted the initial manuscript, provided manuscript feedback and integrated co-author feedback
Impact 1 paper (PMID: 35042687)
Start Year 2016
 
Description Incorporating dose effects in network meta-analysis 
Organisation Saint Michael's Hospital
Country Canada 
Sector Hospitals 
PI Contribution Contributed to the conception and design of this study, and to the manuscript's revision and interpretation of findings
Collaborator Contribution Conceived the study idea, contributed to the study design, developed model codes, prepared datasets, completed analyses, contributed to interpretation of findings, drafted the initial manuscript, provided manuscript feedback and integrated co-author feedback
Impact 1 paper (PMID: 35042687)
Start Year 2016
 
Description Incorporating dose effects in network meta-analysis 
Organisation University of Bern
Country Switzerland 
Sector Academic/University 
PI Contribution Contributed to the conception and design of this study, and to the manuscript's revision and interpretation of findings
Collaborator Contribution Conceived the study idea, contributed to the study design, developed model codes, prepared datasets, completed analyses, contributed to interpretation of findings, drafted the initial manuscript, provided manuscript feedback and integrated co-author feedback
Impact 1 paper (PMID: 35042687)
Start Year 2016
 
Description Incorporating dose effects in network meta-analysis 
Organisation University of Ioannina
Country Greece 
Sector Academic/University 
PI Contribution Contributed to the conception and design of this study, and to the manuscript's revision and interpretation of findings
Collaborator Contribution Conceived the study idea, contributed to the study design, developed model codes, prepared datasets, completed analyses, contributed to interpretation of findings, drafted the initial manuscript, provided manuscript feedback and integrated co-author feedback
Impact 1 paper (PMID: 35042687)
Start Year 2016
 
Description Incorporating dose effects in network meta-analysis 
Organisation University of Toronto
Country Canada 
Sector Academic/University 
PI Contribution Contributed to the conception and design of this study, and to the manuscript's revision and interpretation of findings
Collaborator Contribution Conceived the study idea, contributed to the study design, developed model codes, prepared datasets, completed analyses, contributed to interpretation of findings, drafted the initial manuscript, provided manuscript feedback and integrated co-author feedback
Impact 1 paper (PMID: 35042687)
Start Year 2016
 
Description Individual participant data meta-analysis: A handbook for healthcare research (whole book) 
Organisation Keele University
Country United Kingdom 
Sector Academic/University 
PI Contribution Co-editor. Conceived the book concept and planned the outline. Co-authored multiple chapters
Collaborator Contribution Co-editors. Conceived the book concept and planned the outline. Co-authored multiple chapters
Impact 1 book [ISBN: 978-1-119-33372-2]
Start Year 2015
 
Description Individual participant data meta-analysis: A handbook for healthcare research (whole book) 
Organisation University of York
Department Centre for Reviews and Dissemination (CRD)
Country United Kingdom 
Sector Academic/University 
PI Contribution Co-editor. Conceived the book concept and planned the outline. Co-authored multiple chapters
Collaborator Contribution Co-editors. Conceived the book concept and planned the outline. Co-authored multiple chapters
Impact 1 book [ISBN: 978-1-119-33372-2]
Start Year 2015
 
Description Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis 
Organisation Guy's and St Thomas' NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft
Collaborator Contribution Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft
Impact 1 protocol, and 1 paper (PMID: 34171281)
Start Year 2018
 
Description Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis 
Organisation Hospital Ramón y Cajal
Country Spain 
Sector Hospitals 
PI Contribution Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft
Collaborator Contribution Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft
Impact 1 protocol, and 1 paper (PMID: 34171281)
Start Year 2018
 
Description Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis 
Organisation Institute of Health Carlos III
Country Spain 
Sector Public 
PI Contribution Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft
Collaborator Contribution Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft
Impact 1 protocol, and 1 paper (PMID: 34171281)
Start Year 2018
 
Description Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis 
Organisation Monash University
Country Australia 
Sector Academic/University 
PI Contribution Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft
Collaborator Contribution Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft
Impact 1 protocol, and 1 paper (PMID: 34171281)
Start Year 2018
 
Description Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis 
Organisation Queen Mary University of London
Country United Kingdom 
Sector Academic/University 
PI Contribution Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft
Collaborator Contribution Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft
Impact 1 protocol, and 1 paper (PMID: 34171281)
Start Year 2018
 
Description Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis 
Organisation University of Birmingham
Country United Kingdom 
Sector Academic/University 
PI Contribution Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft
Collaborator Contribution Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft
Impact 1 protocol, and 1 paper (PMID: 34171281)
Start Year 2018
 
Description Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis 
Organisation University of Granada
Country Spain 
Sector Academic/University 
PI Contribution Study conception and design and planned the statistical analyses; accessed, verified and analysed the data; wrote the first draft of the manuscript; commented on the drafts and approved the final draft
Collaborator Contribution Study conception and design and planned the statistical analyses; collected data and did quality assessment; critically revised the manuscript; commented on the drafts and approved the final draft
Impact 1 protocol, and 1 paper (PMID: 34171281)
Start Year 2018
 
Description Long term pregnancy outcomes of women with cancer following fertility preservation: A systematic review and meta-analysis 
Organisation Epsom and St Helier University Hospitals NHS Trust
Country United Kingdom 
Sector Public 
PI Contribution Members of the research team were commented on the protocol, provided feedback and advice during the project, and commented on the final report
Collaborator Contribution Development of the protocol. Performed all trial searches, completed data extraction, analysis and writing the report
Impact 1 protocol (CRD42021269016) and 1 paper (PMID: 36535069)
Start Year 2021
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation Centre Eugène Marquis
Country France 
Sector Public 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation Connolly Hospital Blanchardstown
Country Ireland 
Sector Hospitals 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation Curie Institute Paris (Institut Curie)
Country France 
Sector Academic/University 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation Erasmus MC
Country Netherlands 
Sector Hospitals 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation Gustave-Roussy Institute
Country France 
Sector Academic/University 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation Hospitals Essen-Mitte
Country Germany 
Sector Hospitals 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation Leiden University
Country Netherlands 
Sector Academic/University 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation Lille University Hospital
Country France 
Sector Hospitals 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation NRG Oncology
Country United States 
Sector Charity/Non Profit 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation National Institute for Health Research
Country United Kingdom 
Sector Public 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation Netherlands Cancer Institute (NKI)
Country Netherlands 
Sector Academic/University 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation North Carolina Institute of Medicine
Country United States 
Sector Academic/University 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation Queensland Government
Department Princess Alexandra Hospital (Australia)
Country Australia 
Sector Hospitals 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation St Luke's Hospital, Dublin
Country Ireland 
Sector Hospitals 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation Sun Yat-Sen University
Country China 
Sector Academic/University 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation University of Hong Kong
Country Hong Kong 
Sector Academic/University 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation University of Leipzig
Country Germany 
Sector Academic/University 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation University of Michigan
Country United States 
Sector Academic/University 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation University of Padova
Country Italy 
Sector Academic/University 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation University of Paris-Saclay
Country France 
Sector Academic/University 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation University of Queensland
Country Australia 
Sector Academic/University 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation University of Sydney
Department NHMRC Clinical Trials Centre
Country Australia 
Sector Academic/University 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description MANATEC-02. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma 
Organisation University of Texas
Department M. D. Anderson Cancer Center
Country United States 
Sector Academic/University 
PI Contribution Conception and design, manuscript writing and final approval of manuscript
Collaborator Contribution Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript
Impact Protocol https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=107158 Publication DOI:10.1200/JCO.22.02279
Start Year 2018
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Acibadem University
Country Turkey 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Aix-Marseille University
Country France 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Alexander Fleming Institute
Country Argentina 
Sector Charity/Non Profit 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation American University of Beirut Medical Center
Country Lebanon 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Ankara University
Country Turkey 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Belfast City Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Brussels Saint-Luc University Hospital (UCL)
Country Belgium 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Carolina Urologic Research Center
Country United States 
Sector Public 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Cleveland Clinic
Country United States 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Copenhagen University Hospital
Country Denmark 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Cornell University
Department Weill Cornell Medicine
Country United States 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Dana-Farber Cancer Institute
Country United States 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Duke University
Country United States 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Essen University Hospital
Country Germany 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Fudan University
Country China 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Fundación Marques de Valdecilla
Country Spain 
Sector Charity/Non Profit 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Ghent University Hospital
Country Belgium 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Grochowski Hospital
Country Poland 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Gustave-Roussy Institute
Country France 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Guy's and St Thomas' NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Hong Kong Sanatorium and Hospital
Country Hong Kong 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Hospital 12 de Octubre
Country Spain 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Icahn School of Medicine at Mount Sinai
Country United States 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Innlandet Hospital Trust
Country Norway 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Instituto de Investigación Biomédica de Málaga
Country Spain 
Sector Public 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Kindai University Hospital
Country Japan 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation King Saud University
Country Saudi Arabia 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Massachusetts General Hospital
Country United States 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Massachusetts General Hospital
Country United States 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Medical University of Vienna
Country Austria 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Memorial Sloan Kettering Cancer Center
Country United States 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Mohamed V University
Country Morocco 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Monash University
Country Australia 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Mount Vernon Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation National Cancer Centre Singapore
Country Singapore 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Northwestern University
Department Feinberg School of Medicine
Country United States 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Oregon Health and Science University
Country United States 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Paoli-Calmettes Institute
Country France 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Peter MacCallum Cancer Centre
Country Australia 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Prostate Cancer Foundation
Country Global 
Sector Charity/Non Profit 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Radboud University Nijmegen
Country Netherlands 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Royal Marsden Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Salford Royal Hospital
Department Christie at Salford Royal Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation San Raffaele Hospital
Country Italy 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Santa Chiara Hospital
Country Italy 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Sheffield Teaching Hospitals NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Skåne University Hospital
Country Sweden 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Stanford University
Country United States 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Tampere University Hospital
Country Finland 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Tata Memorial Hospital
Country India 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Tel Aviv University
Country Israel 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation The Methodist Hospital, Houston
Country United States 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation The Hospital Israelita Albert Einstein
Country Spain 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Toho University Medical Center Sakura Hospital
Country Japan 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Tulane Medical Center
Country United States 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University Hospital La Princesa
Country Spain 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University Hospital Schleswig-Holstein
Country Germany 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University Hospitals Seidman Cancer Center
Country United States 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University Medical Center Hamburg-Eppendorf
Country Germany 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Adelaide
Country Australia 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Bern
Country Switzerland 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Bologna
Country Italy 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of British Columbia
Country Canada 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of British Columbia
Country Canada 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of California, Davis
Country United States 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of California, San Francisco
Country United States 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Franche-Comté
Country France 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Lugano
Country Switzerland 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Melbourne
Country Australia 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Miami
Country United States 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Milan
Country Italy 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Minnesota
Department Minnesota NMR Center
Country United States 
Sector Charity/Non Profit 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Minnesota
Country United States 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Montreal
Country Canada 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Paris-Saclay
Country France 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Pennsylvania
Country United States 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Port Harcourt Teaching Hospital
Country Nigeria 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of South Florida
Country United States 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Sydney
Country Australia 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Texas
Department M. D. Anderson Cancer Center
Country United States 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Toronto
Country Canada 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Washington
Country United States 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation University of Zurich
Country Switzerland 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Vall d'Hebron Institute of Oncology
Country Spain 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Walsall College
Country United Kingdom 
Sector Academic/University 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 
Organisation Yokohama City University Medical Centre
Country Japan 
Sector Hospitals 
PI Contribution Writing, reviewing and editing the manuscript
Collaborator Contribution Conceptualization, Methodology, Data Curation, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration
Impact https://doi.org/10.1016/j.ejca.2023.02.018
Start Year 2022
 
Description Multivariate Meta-analysis Using IPD (Chapter 13). In: Individual participant data meta-analysis: A handbook for healthcare research 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Co-authored the chapter
Collaborator Contribution Co-authored the chapter. One partner led writing the chapter and was co-editor of book
Impact 1 book chapter (Chapter 13)
Start Year 2015
 
Description Multivariate Meta-analysis Using IPD (Chapter 13). In: Individual participant data meta-analysis: A handbook for healthcare research 
Organisation Keele University
Country United Kingdom 
Sector Academic/University 
PI Contribution Co-authored the chapter
Collaborator Contribution Co-authored the chapter. One partner led writing the chapter and was co-editor of book
Impact 1 book chapter (Chapter 13)
Start Year 2015
 
Description Preoperative prognostic factors for 5-year survival following pulmonary metastasectomy from colorectal cancer 
Organisation Guy's and St Thomas' NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Conceptualization; Formal analysis; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Writing-review & editing
Collaborator Contribution Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Software; Writing-original draft; Writing-review & editing.
Impact Protocol: PROSPERO (CRD42021247133) Publication: https://doi.org/10.1093/ejcts/ezad059
Start Year 2021
 
Description Preoperative prognostic factors for 5-year survival following pulmonary metastasectomy from colorectal cancer 
Organisation Hillingdon Hospital, Uxbridge
Country United Kingdom 
Sector Hospitals 
PI Contribution Conceptualization; Formal analysis; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Writing-review & editing
Collaborator Contribution Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Software; Writing-original draft; Writing-review & editing.
Impact Protocol: PROSPERO (CRD42021247133) Publication: https://doi.org/10.1093/ejcts/ezad059
Start Year 2021
 
Description Preoperative prognostic factors for 5-year survival following pulmonary metastasectomy from colorectal cancer 
Organisation Royal Victoria Hospital, Belfast
Country United Kingdom 
Sector Hospitals 
PI Contribution Conceptualization; Formal analysis; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Writing-review & editing
Collaborator Contribution Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Software; Writing-original draft; Writing-review & editing.
Impact Protocol: PROSPERO (CRD42021247133) Publication: https://doi.org/10.1093/ejcts/ezad059
Start Year 2021
 
Description Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions 
Organisation Albert Ludwig University of Freiburg
Department Faculty of Medicine
Country Germany 
Sector Academic/University 
PI Contribution Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript
Collaborator Contribution Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript
Impact 1 paper (PMID: 34689743)
Start Year 2017
 
Description Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript
Collaborator Contribution Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript
Impact 1 paper (PMID: 34689743)
Start Year 2017
 
Description Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions 
Organisation Li Ka Shing Foundation
Country Hong Kong 
Sector Charity/Non Profit 
PI Contribution Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript
Collaborator Contribution Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript
Impact 1 paper (PMID: 34689743)
Start Year 2017
 
Description Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions 
Organisation University of Bern
Department Institute of Social and Preventive Medicine
Country Switzerland 
Sector Academic/University 
PI Contribution Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript
Collaborator Contribution Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript
Impact 1 paper (PMID: 34689743)
Start Year 2017
 
Description Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions 
Organisation University of Bristol
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript
Collaborator Contribution Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript
Impact 1 paper (PMID: 34689743)
Start Year 2017
 
Description Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions 
Organisation University of Ioannina
Country Greece 
Sector Academic/University 
PI Contribution Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript
Collaborator Contribution Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript
Impact 1 paper (PMID: 34689743)
Start Year 2017
 
Description Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions 
Organisation University of Paris - Descartes
Country France 
Sector Academic/University 
PI Contribution Contributed to conceptualizing the study, read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript
Collaborator Contribution Conceptualized the study; designed and coordinated the study; screened literature and the literature search results; abstracted, coded, cleaned and analysed the data; participated in all the calibration exercises of data collection, helped resolve data discrepancies, analysed the data; interpreted the findings; drafted manuscript and read, provided substantial edits and/or comments on the manuscript, and approved the final version of the manuscript
Impact 1 paper (PMID: 34689743)
Start Year 2017
 
Description Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer 
Organisation Aix-Marseille University
Country France 
Sector Academic/University 
PI Contribution Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Collaborator Contribution Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Impact Publication; https://doi.org/10.1200/JCO.23.01535
Start Year 2020
 
Description Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer 
Organisation Christus Health
Country United States 
Sector Hospitals 
PI Contribution Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Collaborator Contribution Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Impact Publication; https://doi.org/10.1200/JCO.23.01535
Start Year 2020
 
Description Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer 
Organisation Dana-Farber Cancer Institute
Country United States 
Sector Hospitals 
PI Contribution Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Collaborator Contribution Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Impact Publication; https://doi.org/10.1200/JCO.23.01535
Start Year 2020
 
Description Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer 
Organisation Duke University
Country United States 
Sector Academic/University 
PI Contribution Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Collaborator Contribution Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Impact Publication; https://doi.org/10.1200/JCO.23.01535
Start Year 2020
 
Description Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer 
Organisation Erasmus MC
Country Netherlands 
Sector Hospitals 
PI Contribution Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Collaborator Contribution Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Impact Publication; https://doi.org/10.1200/JCO.23.01535
Start Year 2020
 
Description Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer 
Organisation Fred Hutchinson Cancer Research Center (FHCRC)
Country United States 
Sector Academic/University 
PI Contribution Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Collaborator Contribution Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Impact Publication; https://doi.org/10.1200/JCO.23.01535
Start Year 2020
 
Description Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer 
Organisation Johns Hopkins University
Country United States 
Sector Academic/University 
PI Contribution Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Collaborator Contribution Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Impact Publication; https://doi.org/10.1200/JCO.23.01535
Start Year 2020
 
Description Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer 
Organisation Massachusetts General Hospital
Country United States 
Sector Hospitals 
PI Contribution Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Collaborator Contribution Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Impact Publication; https://doi.org/10.1200/JCO.23.01535
Start Year 2020
 
Description Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer 
Organisation Memorial Sloan Kettering Cancer Center
Country United States 
Sector Academic/University 
PI Contribution Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Collaborator Contribution Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Impact Publication; https://doi.org/10.1200/JCO.23.01535
Start Year 2020
 
Description Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer 
Organisation Northwestern University
Country United States 
Sector Academic/University 
PI Contribution Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Collaborator Contribution Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Impact Publication; https://doi.org/10.1200/JCO.23.01535
Start Year 2020
 
Description Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer 
Organisation Royal Marsden NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Collaborator Contribution Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Impact Publication; https://doi.org/10.1200/JCO.23.01535
Start Year 2020
 
Description Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer 
Organisation University of Adelaide
Country Australia 
Sector Academic/University 
PI Contribution Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Collaborator Contribution Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Impact Publication; https://doi.org/10.1200/JCO.23.01535
Start Year 2020
 
Description Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer 
Organisation University of Hasselt
Department International Drug Development Institute
Country Belgium 
Sector Academic/University 
PI Contribution Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Collaborator Contribution Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Impact Publication; https://doi.org/10.1200/JCO.23.01535
Start Year 2020
 
Description Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer 
Organisation University of Kyoto
Country Japan 
Sector Academic/University 
PI Contribution Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Collaborator Contribution Conception and design; Financial support; Administrative support; Provision of study materials or patients; Collection and assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript
Impact Publication; https://doi.org/10.1200/JCO.23.01535
Start Year 2020
 
Description Rationale for Embarking on an IPD Meta-analysis Project (Chapter 2). In: Individual participant data meta-analysis: A handbook for healthcare research 
Organisation Keele University
Country United Kingdom 
Sector Academic/University 
PI Contribution Led writing of chapter. Co-editor of book
Collaborator Contribution Co-authored the chapter, two partners co-editors of book
Impact 1 book chapter (Chapter 2)
Start Year 2015
 
Description Rationale for Embarking on an IPD Meta-analysis Project (Chapter 2). In: Individual participant data meta-analysis: A handbook for healthcare research 
Organisation Queen's University Belfast
Country United Kingdom 
Sector Academic/University 
PI Contribution Led writing of chapter. Co-editor of book
Collaborator Contribution Co-authored the chapter, two partners co-editors of book
Impact 1 book chapter (Chapter 2)
Start Year 2015
 
Description Rationale for Embarking on an IPD Meta-analysis Project (Chapter 2). In: Individual participant data meta-analysis: A handbook for healthcare research 
Organisation University of Liverpool
Country United Kingdom 
Sector Academic/University 
PI Contribution Led writing of chapter. Co-editor of book
Collaborator Contribution Co-authored the chapter, two partners co-editors of book
Impact 1 book chapter (Chapter 2)
Start Year 2015
 
Description Rationale for Embarking on an IPD Meta-analysis Project (Chapter 2). In: Individual participant data meta-analysis: A handbook for healthcare research 
Organisation University of York
Country United Kingdom 
Sector Academic/University 
PI Contribution Led writing of chapter. Co-editor of book
Collaborator Contribution Co-authored the chapter, two partners co-editors of book
Impact 1 book chapter (Chapter 2)
Start Year 2015
 
Description ReducIng Self-harm in Adolescents: Individual Participant Data meta-analysis 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Member of Steering Committee. Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact I protocol (http://dx.doi.org/10.1136/bmjopen-2021-049255) and 1 SAP.
Start Year 2019
 
Description ReducIng Self-harm in Adolescents: Individual Participant Data meta-analysis 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Member of Steering Committee. Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact I protocol (http://dx.doi.org/10.1136/bmjopen-2021-049255) and 1 SAP.
Start Year 2019
 
Description ReducIng Self-harm in Adolescents: Individual Participant Data meta-analysis 
Organisation University of Leeds
Country United Kingdom 
Sector Academic/University 
PI Contribution Member of Steering Committee. Advising on practical and methodological aspects including commenting on the protocol and SAP.
Collaborator Contribution Study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript
Impact I protocol (http://dx.doi.org/10.1136/bmjopen-2021-049255) and 1 SAP.
Start Year 2019
 
Description Sharing individual participant data: through a systematic reviewer lens 
Organisation University of York
Department Centre for Reviews and Dissemination (CRD)
Country United Kingdom 
Sector Academic/University 
PI Contribution Conceived the idea for the article and drafted the manuscript, approved the final manuscript.
Collaborator Contribution Input into the manuscript and approved the final manuscript
Impact 1 manuscript [doi.org/10.1186/s13063-021-05787-4]
Start Year 2021
 
Description The Two-stage Approach to IPD Meta-analysis (Chapter 5). In: Individual participant data meta-analysis: A handbook for healthcare research 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Co-author of the chapter
Collaborator Contribution Co-authors of the chapter. One partner led writing the chapter and co-editor of book
Impact 1 book chapter (Chapter 5)
Start Year 2015
 
Description The Two-stage Approach to IPD Meta-analysis (Chapter 5). In: Individual participant data meta-analysis: A handbook for healthcare research 
Organisation Keele University
Country United Kingdom 
Sector Academic/University 
PI Contribution Co-author of the chapter
Collaborator Contribution Co-authors of the chapter. One partner led writing the chapter and co-editor of book
Impact 1 book chapter (Chapter 5)
Start Year 2015
 
Description The Two-stage Approach to IPD Meta-analysis (Chapter 5). In: Individual participant data meta-analysis: A handbook for healthcare research 
Organisation University Medical Center Utrecht (UMC)
Country Netherlands 
Sector Academic/University 
PI Contribution Co-author of the chapter
Collaborator Contribution Co-authors of the chapter. One partner led writing the chapter and co-editor of book
Impact 1 book chapter (Chapter 5)
Start Year 2015
 
Description The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis 
Organisation Camden and Islington NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report.
Collaborator Contribution Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report
Impact 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056)
Start Year 2019
 
Description The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis 
Organisation University of Bristol
Country United Kingdom 
Sector Academic/University 
PI Contribution Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report.
Collaborator Contribution Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report
Impact 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056)
Start Year 2019
 
Description The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis 
Organisation University of California
Country United States 
Sector Academic/University 
PI Contribution Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report.
Collaborator Contribution Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report
Impact 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056)
Start Year 2019
 
Description The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis 
Organisation University of Exeter
Department College of Medicine and Health
Country United Kingdom 
Sector Academic/University 
PI Contribution Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report.
Collaborator Contribution Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report
Impact 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056)
Start Year 2019
 
Description The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis 
Organisation University of Exeter
Country United Kingdom 
Sector Academic/University 
PI Contribution Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report.
Collaborator Contribution Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report
Impact 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056)
Start Year 2019
 
Description The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis 
Organisation University of Pennsylvania
Country United States 
Sector Academic/University 
PI Contribution Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report.
Collaborator Contribution Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report
Impact 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056)
Start Year 2019
 
Description The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis 
Organisation University of Southampton
Country United Kingdom 
Sector Academic/University 
PI Contribution Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report.
Collaborator Contribution Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report
Impact 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056)
Start Year 2019
 
Description The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis 
Organisation University of York
Department Department of Health Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report.
Collaborator Contribution Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report
Impact 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056)
Start Year 2019
 
Description The contribution of depressive 'disorder characteristics' to determinations of prognosis for adults with depression: an individual patient data meta-analysis 
Organisation Vanderbilt University
Country United States 
Sector Academic/University 
PI Contribution Member of the research team was a member of the Project Advisory Group, provided input on the protocol and statistical analysis plan, provided feedback and advice during the project, and commented on the final report.
Collaborator Contribution Development of the protocol and the statistical analysis plan. Obtained the data and information about the data. Performed the analysis. Led the writing of all sections of the report
Impact 1 protocol, and 2 papers (PMID: 33849685, PMID: 33548056)
Start Year 2019
 
Description Use of multiple covariates in assessing treatment-effect modifiers: A methodological review of individual participant data meta-analyses 
Organisation Queen Mary University of London
Department Barts and The London School of Medicine and Dentistry
Country United Kingdom 
Sector Academic/University 
PI Contribution Conceptualization; formal analysis; investigation; supervision; writing - original draft; Writing - review and editing.
Collaborator Contribution Investigation; resources; supervision; writing - review and editing
Impact Protocol: PROSPERO CRD42019126768 Publications: https://doi.org/10.1002/jrsm.1674; 10.1016/j.jclinepi.2023.04.014; 10.1016/j.jclinepi.2023.04.013
Start Year 2021
 
Description Use of multiple covariates in assessing treatment-effect modifiers: A methodological review of individual participant data meta-analyses 
Organisation University of Birmingham
Country United Kingdom 
Sector Academic/University 
PI Contribution Conceptualization; formal analysis; investigation; supervision; writing - original draft; Writing - review and editing.
Collaborator Contribution Investigation; resources; supervision; writing - review and editing
Impact Protocol: PROSPERO CRD42019126768 Publications: https://doi.org/10.1002/jrsm.1674; 10.1016/j.jclinepi.2023.04.014; 10.1016/j.jclinepi.2023.04.013
Start Year 2021
 
Description Using individual participant data to improve network meta-analysis projects 
Organisation Keele University
Department School of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Members of the research team provided feedback and advice during the project, and commented on the final manuscript
Collaborator Contribution Wrote the first draft of the manuscript; revised draft based on comments from other authors and reviewers; provided advice and feedback; commented on final manuscript and submitted the manuscript
Impact 1 paper (PMID: 35948411)
Start Year 2022
 
Description Using individual participant data to improve network meta-analysis projects 
Organisation University of Bern
Department Institute of Social and Preventive Medicine
Country Switzerland 
Sector Academic/University 
PI Contribution Members of the research team provided feedback and advice during the project, and commented on the final manuscript
Collaborator Contribution Wrote the first draft of the manuscript; revised draft based on comments from other authors and reviewers; provided advice and feedback; commented on final manuscript and submitted the manuscript
Impact 1 paper (PMID: 35948411)
Start Year 2022
 
Description Using individual participant data to improve network meta-analysis projects 
Organisation University of Bristol
Country United Kingdom 
Sector Academic/University 
PI Contribution Members of the research team provided feedback and advice during the project, and commented on the final manuscript
Collaborator Contribution Wrote the first draft of the manuscript; revised draft based on comments from other authors and reviewers; provided advice and feedback; commented on final manuscript and submitted the manuscript
Impact 1 paper (PMID: 35948411)
Start Year 2022
 
Description Using individual participant data to improve network meta-analysis projects 
Organisation University of Liverpool
Country United Kingdom 
Sector Academic/University 
PI Contribution Members of the research team provided feedback and advice during the project, and commented on the final manuscript
Collaborator Contribution Wrote the first draft of the manuscript; revised draft based on comments from other authors and reviewers; provided advice and feedback; commented on final manuscript and submitted the manuscript
Impact 1 paper (PMID: 35948411)
Start Year 2022
 
Description Using individual participant data to improve network meta-analysis projects 
Organisation University of York
Department Centre for Reviews and Dissemination (CRD)
Country United Kingdom 
Sector Academic/University 
PI Contribution Members of the research team provided feedback and advice during the project, and commented on the final manuscript
Collaborator Contribution Wrote the first draft of the manuscript; revised draft based on comments from other authors and reviewers; provided advice and feedback; commented on final manuscript and submitted the manuscript
Impact 1 paper (PMID: 35948411)
Start Year 2022
 
Description Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel? 
Organisation Catholic University of Louvain
Country Belgium 
Sector Academic/University 
PI Contribution Conceived of and designed the study protocol; completed the literature searches; statistical analysis plan; processed and checked the received data and liaised with individual trial teams to resolve queries; completed risk of bias assessments; statistical analysis; drafted report; finalised and submitted report.
Collaborator Contribution Conceived of and designed the study protocol; supplied the individual participant data; reviewed and submitted comments on early versions and agreed the final version for submission
Impact Protocol: PROSPERO, CRD42019140591. Publication: https://doi.org/10.1016/S1470-2045(23)00230-9
Start Year 2021
 
Description Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel? 
Organisation Dana-Farber Cancer Institute
Country United States 
Sector Hospitals 
PI Contribution Conceived of and designed the study protocol; completed the literature searches; statistical analysis plan; processed and checked the received data and liaised with individual trial teams to resolve queries; completed risk of bias assessments; statistical analysis; drafted report; finalised and submitted report.
Collaborator Contribution Conceived of and designed the study protocol; supplied the individual participant data; reviewed and submitted comments on early versions and agreed the final version for submission
Impact Protocol: PROSPERO, CRD42019140591. Publication: https://doi.org/10.1016/S1470-2045(23)00230-9
Start Year 2021
 
Description Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel? 
Organisation Institute of Cancer Research UK
Country United Kingdom 
Sector Academic/University 
PI Contribution Conceived of and designed the study protocol; completed the literature searches; statistical analysis plan; processed and checked the received data and liaised with individual trial teams to resolve queries; completed risk of bias assessments; statistical analysis; drafted report; finalised and submitted report.
Collaborator Contribution Conceived of and designed the study protocol; supplied the individual participant data; reviewed and submitted comments on early versions and agreed the final version for submission
Impact Protocol: PROSPERO, CRD42019140591. Publication: https://doi.org/10.1016/S1470-2045(23)00230-9
Start Year 2021
 
Description Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel? 
Organisation Paoli-Calmettes Institute
Country France 
Sector Hospitals 
PI Contribution Conceived of and designed the study protocol; completed the literature searches; statistical analysis plan; processed and checked the received data and liaised with individual trial teams to resolve queries; completed risk of bias assessments; statistical analysis; drafted report; finalised and submitted report.
Collaborator Contribution Conceived of and designed the study protocol; supplied the individual participant data; reviewed and submitted comments on early versions and agreed the final version for submission
Impact Protocol: PROSPERO, CRD42019140591. Publication: https://doi.org/10.1016/S1470-2045(23)00230-9
Start Year 2021
 
Description Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel? 
Organisation Salford Royal Hospital
Department Christie at Salford Royal Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution Conceived of and designed the study protocol; completed the literature searches; statistical analysis plan; processed and checked the received data and liaised with individual trial teams to resolve queries; completed risk of bias assessments; statistical analysis; drafted report; finalised and submitted report.
Collaborator Contribution Conceived of and designed the study protocol; supplied the individual participant data; reviewed and submitted comments on early versions and agreed the final version for submission
Impact Protocol: PROSPERO, CRD42019140591. Publication: https://doi.org/10.1016/S1470-2045(23)00230-9
Start Year 2021
 
Description Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel? 
Organisation University of Adelaide
Country Australia 
Sector Academic/University 
PI Contribution Conceived of and designed the study protocol; completed the literature searches; statistical analysis plan; processed and checked the received data and liaised with individual trial teams to resolve queries; completed risk of bias assessments; statistical analysis; drafted report; finalised and submitted report.
Collaborator Contribution Conceived of and designed the study protocol; supplied the individual participant data; reviewed and submitted comments on early versions and agreed the final version for submission
Impact Protocol: PROSPERO, CRD42019140591. Publication: https://doi.org/10.1016/S1470-2045(23)00230-9
Start Year 2021
 
Description Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel? 
Organisation University of Paris-Saclay
Country France 
Sector Academic/University 
PI Contribution Conceived of and designed the study protocol; completed the literature searches; statistical analysis plan; processed and checked the received data and liaised with individual trial teams to resolve queries; completed risk of bias assessments; statistical analysis; drafted report; finalised and submitted report.
Collaborator Contribution Conceived of and designed the study protocol; supplied the individual participant data; reviewed and submitted comments on early versions and agreed the final version for submission
Impact Protocol: PROSPERO, CRD42019140591. Publication: https://doi.org/10.1016/S1470-2045(23)00230-9
Start Year 2021
 
Description Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel? 
Organisation University of Wisconsin-Madison
Country United States 
Sector Academic/University 
PI Contribution Conceived of and designed the study protocol; completed the literature searches; statistical analysis plan; processed and checked the received data and liaised with individual trial teams to resolve queries; completed risk of bias assessments; statistical analysis; drafted report; finalised and submitted report.
Collaborator Contribution Conceived of and designed the study protocol; supplied the individual participant data; reviewed and submitted comments on early versions and agreed the final version for submission
Impact Protocol: PROSPERO, CRD42019140591. Publication: https://doi.org/10.1016/S1470-2045(23)00230-9
Start Year 2021
 
Title metafloat 
Description metafloat: estimation of covariate interactions and subgroup-specific treatment effects in meta-analysis 
Type Of Technology Software 
Year Produced 2023 
Open Source License? Yes  
Impact The "metafloat" package was developed to implement the methodology described in Godolphin et al (Res Syn Meth 2023, https://doi.org/10.1002/jrsm.1590). As a result of dissemination activity surrounding this paper, the authors have received communication from users of the software. Furthermore, elements of the software have been used to create figures within notable recent papers including Shankar-Hari et al (JAMA 2021, https://doi.org/10.1001/jama.2021.11330) and Vale et al (Lancet Oncol 2023, https://doi.org/10.1016/S1470-2045(23)00230-9). 
URL https://github.com/UCL/metafloat
 
Title metan update 
Description Update of metan: fixed and random-effects meta-analysis 
Type Of Technology Software 
Year Produced 2024 
Open Source License? Yes  
Impact The "metan" package was originally developed in 1998 by experts in the field, with major updates in 2010 and 2020. As of 2020, it is maintained by David Fisher at MRC Clinical Trials Unit at UCL, with the most recent update in September 2023. Although Stata now has built-in meta-analysis functionality, there remains a need for a comprehensive, adaptable user-written package. In the 12 months between July 2022 and June 2023, "metan" was downloaded on average 3,800 times per month. 
URL https://ideas.repec.org/c/boc/bocode/s456798.html
 
Title mvmeta update 
Description Update of mvmeta: multivariate meta-analysis 
Type Of Technology Software 
Year Produced 2022 
Open Source License? Yes  
Impact The original software has been used to improve precision and reduce bias in several published meta-analysis, and is an essential part of the widely used "network" package for performing network meta-analysis in Stata. The update has no impact as yet. 
URL https://ideas.repec.org/c/boc/bocode/s456970.html
 
Description A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Response to an opinion piece (published in Nature) critical of aggregate data meta-analysis for COVID 19, to demonstrate how a collaborative and prospective approach to meta-analysis can produce timely, reliable and thorough aggregate data meta-analysis in COVID 19.
Year(s) Of Engagement Activity 2021
 
Description A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact JT and SB invited to host a live webinar for Cochrane Methods Support Unit. 'How can the framework for prospective, adaptive meta-analysis (FAME) be used to improve the quality of Cochrane reviews?' (9 March 2023)
Year(s) Of Engagement Activity 2023
 
Description A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact Invited to contribute to Cochrane's response to the WHO consultation 'World Health Assembly Resolution on strengthening clinical trials'. Focussing on how FAME Framework can help to reduce research waste.
Year(s) Of Engagement Activity 2022
 
Description A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Title: How can a framework for prospective, adaptive meta-analysis (FAME) improve the quality of Cochrane reviews?
Presenter: Jayne Tierney
Cochrane Colloguium 2023, London
Oral Presentations - Wednesday 6th September - 15:05-15:25
Year(s) Of Engagement Activity 2023
URL https://events.cochrane.org/colloquium-2023/schedule
 
Description A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Submitted a nomination to the Cochrane Reward Prize to demonstrate how a collaborative and prospective approach to meta-analysis can produce timely, reliable and thorough aggregate data meta-analysis in COVID 19, thereby reducing research waste. The submission made it to the second round of judging.
Year(s) Of Engagement Activity 2021
 
Description A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Title: How can the framework for prospective, adaptive meta-analysis (FAME) be used to improve the quality of Cochrane reviews? Presentation given by Jayne Tierney for the Cochrane Methods Support Unit, aimed at Cochrane reviewers. Aug 2023
Year(s) Of Engagement Activity 2023
URL https://training.cochrane.org/resource/msu-web-clinic-august-2023
 
Description A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A series of Tweets directed at different audiences e.g. systematic reviewers; clinicians, and making use of collaborators influential on twitter. News story on MRC CTU@ UCL website and STOPCAPM1 website
Year(s) Of Engagement Activity 2021
 
Description A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Presentation at meeting of Methodologists to describe the considerable dissemination activities that took place around the publication of the FAME manuscript
Year(s) Of Engagement Activity 2021
 
Description A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact The MiM meeting is a seminar series bringing together researchers who work in meta-analysis methodology. Presenting this work to this audience was an opportunity to promote the value of the approach taken to this review and the benefits it brings. It sparked interest and discussion among those keen to adapt their own approach to meta-analysis in similar ways
Year(s) Of Engagement Activity 2021
 
Description A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A short questionnaire was emailed to a range of Systematic Review experts, asking them to read the manuscript and then respond as to whether they liked it or not and why, and whether they thought they would use the methods or not and why. This helped identify barriers and concerns that will influence future engagement and research on FAME
Year(s) Of Engagement Activity 2021
 
Description Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Twitter posts (story and thread); News story on MRC CTU @ UCL website
Year(s) Of Engagement Activity 2022
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The world evidence based healthcare day 2021 was a call to the global evidence community to share their experiences, expertise and stories on infodemic management in the wake of the COVID pandemic. It is a global initiative that aims to raise awareness of the need for better evidence to inform healthcare policy, practice and decision making in order to improve health outcomes globally. It also provides an opportunity to participate in debate and to celebrate the impact of individuals and organisations worldwide, recognising the work of dedicated researchers, policymakers and health professionals in improving health outcomes.
Year(s) Of Engagement Activity 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Used a series of tweet to promote the key messages of the review as well as aspects of the methodology used to highlight the value in the approach. The tweets were retweeted, and quoted by more than 60 news outlets. The Altmetric score is 871, putting the article in the top 5% of all research outputs, largely driven by activity on Twitter.
Year(s) Of Engagement Activity 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The MiM meeting is a seminar series bringing together researchers who work in meta-analysis methodology. Presenting this work to this audience was an opportunity to promote the value of the approach taken to this review and the benefits it brings. It sparked interest and discussion among those keen to adapt their own approach to meta-analysis in similar ways
Year(s) Of Engagement Activity 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact A press release to coincide with the publication of this work and the accompanying WHO Guideline was written and disseminated in conjunction with Kings College London, University of Bristol, UCL and WHO teams. It was picked up in a number of media outlets, including Bloomberg, Reuters, Daily Mail, NBC News, AFP, and dozens of international titles
Year(s) Of Engagement Activity 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Presented the findings of the IL6 review to the MRCCTU staff as part of the lunchtime seminar series, and answered queries both about the methods used, results and their impact and meaning.
Year(s) Of Engagement Activity 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact Presented the preliminary results of the IL-6 meta-analysis to the WHO Guideline development group and answered questions and queries on the methods and results. This is the group responsible for deciding whether new WHO guidelines will recommend a treatment or not based on the evidence available to them
Year(s) Of Engagement Activity 2021
 
Description Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This summarised the process and merits of the approach taken to this piece of research, the value of collaboration and how extensive and efficient the process was. It was included on the MRC CTU website and promoted on Twitter
Year(s) Of Engagement Activity 2021
URL https://www.mrcctu.ucl.ac.uk/our-research/methodology/meta-analysis/blog-interlukin-6-antagonists-im...
 
Description Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Tweets were written and sent publicising the findings of this paper
Year(s) Of Engagement Activity 2022
 
Description Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Pre-publication manuscript was shared with Public Health England. as Tocilizumab, an interleukin-6 receptor antagonist that was shown to reduce mortality for patients hospitalised with COVID-19 and stores in England were running low. The paper provided evidence that Sarilumab (an alternative interleukin-6 receptor antagonist) had similar mortality benefits
Year(s) Of Engagement Activity 2022
 
Description Biarritz NMA course 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A 3-day course on network meta-analysis was delivered to 30 participants, mostly from Europe.
Year(s) Of Engagement Activity 2022
URL https://www.cer-methods.com/2021/12/09/nmacourse/
 
Description COCROACH Collaboration: prospective, individual participant data meta-analysis of randomised trials 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Relating to publication of Al-Shahi Salman R (doi:10.1016/S1474-4422(23)00315-0)

Podcast for the Lancet Neurology by first Author of paper Rustam Al-Shahi Salman
Year(s) Of Engagement Activity 2023
URL https://www.buzzsprout.com/1391383/13968688
 
Description COCROACH Collaboration: prospective, individual participant data meta-analysis of randomised trials 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Relating to publication of Al Shai Salman et al (doi: 10.1016/S1474-4422(23)00315-0)

Title: THE EFFECTS OF LONG-TERM ORAL ANTICOAGULANT AGENTS FOR ATRIAL FIBRILLATION (AF) AFTER INTRACRANIAL HAEMORRHAGE (ICH): PROSPECTIVE INDIVIDUAL PARTICIPANT DATA META-ANALYSIS (IPDMA) OF RANDOMISED CONTROLLED TRIALS
Presenter: Rustam Al Shai Salman
Conference: 15th World Stroke Congress 2023, Toronto
Year(s) Of Engagement Activity 2023
URL https://cslide.ctimeetingtech.com/wsc23/attendee/person/94
 
Description Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Thread of short posts taking readers through the paper step by step. This series of posts was posted both on Twitter and Mastodon
Year(s) Of Engagement Activity 2023
 
Description Estimating interactions and subgroup-specific treatment effects in meta-analysis without aggregation bias: A within-trial framework 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact Two of the authors (PG, DF) engaged with two patient and public representatives to help improve dissemination of the methodology and reach a wider audience. The PPI members contributed to writing and editing content to be shared on social platforms.
Year(s) Of Engagement Activity 2022
 
Description Estimating interactions and subgroup-specific treatment effects in meta-analysis without aggregation bias: A within-trial framework 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact After engagement with the PPI members, authors wrote (with PPI members support) content for a news story hosted the MRC CTU website and an associated twitter thread that was widely shared. After this content was live, the authors have since been contacted by two separate researchers asking for clarification on the method and advice implementing the method in their own studies
Year(s) Of Engagement Activity 2022
 
Description Estimating interactions and subgroup-specific treatment effects in meta-analysis without aggregation bias: A within-trial framework 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Conference paper presentation at the Society for Clinical Trials Annual Meeting for both an in-person and virtual audience. The talk and paper won the Thomas Chalmer's Award from the Society
Year(s) Of Engagement Activity 2022
 
Description Individual Participant Data Meta-analysis: A Handbook for Healthcare Research 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Contributed to website aimed at promoting the book
Year(s) Of Engagement Activity 2021,2022
URL https://www.ipdma.co.uk/textbook
 
Description Individual participant data meta-analysis: A handbook for healthcare research 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Tweets announcing publication through the MRC CTU Twitter account
Year(s) Of Engagement Activity 2021
 
Description Interactions in MA: Subgroup effect estimates consistent with the "deft" interaction (common-effects) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Title: Reliably estimating interactions and subgroup effects in aggregate data meta-analysis
Presenter: Peter Godolphin
Cochrane Colloquium 2023, London
(https://events.cochrane.org/colloquium-2023/schedule) Oral Presentations, Tuesday, 5 September 2023, 11:25 - 11:45
This presentation won 2023 Thomas C Chalmers Award - Best Long Oral
Year(s) Of Engagement Activity 2023
URL https://community.cochrane.org/news/winner-2023-thomas-c-chalmers-award-best-long-oral-presentation-...
 
Description Interactions in MA: Subgroup effect estimates consistent with the "deft" interaction (common-effects) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Relating to publication: Godolphin et al (doi: 10.1002/jrsm.1590.)

Title: Identifying who benefits most from treatments: estimating interactions and subgroup effects in aggregate data meta-analysis [January 2024]
Presenter: Peter Godolphin
Cochrane Learning Events - Methods - Meta-analysis and other statistical methods (January 2024). Cochrane Learning Live is a series of online learning events open to everyone
Year(s) Of Engagement Activity 2023
URL https://training.cochrane.org/resource/estimating-interactions-and-subgroup-effects-in-aggregate-dat...
 
Description Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact A blog post from the co-author discussing the research in the context of her personal experience as a pregnant woman at risk of iron deficiency anaemia.
Year(s) Of Engagement Activity 2021
URL https://www.qmul.ac.uk/media/news/2021/smd/pregnant-women-need-more-information-and-options-for-trea...
 
Description Meta-analyses based on summary data can provide timely, thorough and reliable evidence: don't dismiss them yet 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The work in this paper was presented during the national 2022 'Meta-Analysis in Medicine' meeting (that had invited international colleagues) of statisticians who specialise in meta-analysis, including some PhD students. The talk sparked numerous questions from the audience.
Year(s) Of Engagement Activity 2022
 
Description Meta-analyses based on summary data can provide timely, thorough and reliable evidence: don't dismiss them yet 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A twitter thread summarising the rationale for this work and the key messages was written by one of the authors. To date, this has had over 300 engagements. The journal, with over 300K followers also widely shared the work and created an infographic with a quote from the paper that has been retweeted widely.
Year(s) Of Engagement Activity 2022
 
Description Presentation: 'metan: a Stata package for performing aggregate-data meta-analysis' 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact The updated version of the STATA program METAN was presented at the UCL-wide workshop "Writing methodological software for statistical applications in health". Presentation entitled "metan: a Stata package for performing aggregate-data meta-analysis"
Year(s) Of Engagement Activity 2022
 
Description Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Relating to publication of: Halabi S et al. Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2024 Jan 5:JCO2301535. doi: 10.1200/JCO.23.01535. Epub ahead of print. PMID: 38181323.

On publication, news story on MRC CTU at UCL website (www.mrcctu@ucl.ac.uk) and www.STOPCAPM1.org
https://www.mrcctu.ucl.ac.uk/news/news-stories/2024/february/new-prostate-cancer-treatments-could-reach-men-sooner/
http://www.stopcapm1.org/news/news-stories/2024/february/new-prostate-cancer-treatments-could-reach-men-sooner/
Year(s) Of Engagement Activity 2023
URL https://www.mrcctu.ucl.ac.uk/news/news-stories/2024/february/new-prostate-cancer-treatments-could-re...
 
Description Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Relating to publication of Halabi S et al. (doi: 10.1200/JCO.23.01535)

On publication, a press release from the Prostate Cancer Foundation (PCF), USA. Title: New Prostate Cancer Foundation-Funded Research To Speed Up Prostate Cancer Clinical Trials Worldwide

The press release led to the following news outlets reporting this work
MSN; Yahoo; Morningstar; PR Newswire; OncLive; MedicalXpress; Drugs.com and ProfitQuotes
Year(s) Of Engagement Activity 2024
URL https://www.pcf.org/news/new-prostate-cancer-foundation-funded-research-to-speed-up-prostate-cancer-...
 
Description Sharing individual participant data: through a systematic reviewer lens 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Tweets and new story on MRC CTU @ UCL website
Year(s) Of Engagement Activity 2021
 
Description Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: A World Health Organization-coordinated prospective meta-analysis of randomised trials 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Title: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: A World Health Organization-coordinated prospective meta-analysis of randomised trials
Author: Mikhail Kosiborod, MD on behalf of The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group.
Conference: European Society of Cardiologists Congress, August 28th, 2023

Full paper has been submitted to a journal
Year(s) Of Engagement Activity 2023
URL https://esc365.escardio.org/home
 
Description Two-stage or not two-stage? That is the question for IPD meta-analysis projects 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Relating to the publication of Riley et al: (doi: 10.1002/jrsm.1661)

Engagement on twitter/x by first author (Richard Riley)
https://x.com/Richard_D_Riley/status/1693978578881302791
https://x.com/Richard_D_Riley/status/1758126377599950898
https://x.com/Richard_D_Riley/status/1711417266275807496
Year(s) Of Engagement Activity 2023
 
Description Use of multiple covariates in assessing treatment-effect modifiers: A methodological review of individual participant data meta-analyses 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Relating to: Godolphin PJ et al (doi:10.1002/jrsm.1674); Marlin N et al (doi: 10.1016/j.jclinepi.2023.04.014) and Marlin N et al. (doi: 10.1016/j.jclinepi.2023.04.013)

Presentation Title: Estimation of treatment-covariate interactions in individual participant data meta-analyses of randomised trials: What questions are we addressing?
Event: Meta-analysis in Medicine (MiM), 28.11.2023
Audience: statisticians/methodologists working in meta-analysis
Year(s) Of Engagement Activity 2023
 
Description Use of multiple covariates in assessing treatment-effect modifiers: A methodological review of individual participant data meta-analyses 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact Relating to: Godolphin PJ et al (doi:10.1002/jrsm.1674); Marlin N et al (doi: 10.1016/j.jclinepi.2023.04.014) and Marlin N et al. (doi: 10.1016/j.jclinepi.2023.04.013)
Presentation Title: Use of multiple covariates in assessing treatment-effect modifiers: A methodological review of IPD meta-analyses
Event: Society for Research Synthesis Methodology, 2023
Audience: statisticians/methodologists working in meta-analysis
Year(s) Of Engagement Activity 2023
 
Description Use of multiple covariates in assessing treatment-effect modifiers: A methodological review of individual participant data meta-analyses 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Relating to: Godolphin PJ et al (doi:10.1002/jrsm.1674); Marlin N et al (doi: 10.1016/j.jclinepi.2023.04.014) and Marlin N et al. (doi: 10.1016/j.jclinepi.2023.04.013)

Twitter posts to draw attention to the publications by Peter Godolphin
https://twitter.com/petegodolphin/status/1671902761523240961
https://twitter.com/MRCCTU/status/1712479530122969234
Year(s) Of Engagement Activity 2023
URL https://twitter.com/petegodolphin/status/1671902761523240961
 
Description Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trial 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Relating to publication of: Vale CL et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol. 2023 Jul;24(7):783-797. doi: 10.1016/S1470-2045(23)00230-9. PMID: 37414011.

Briefing Paper; July 2023, Issue 34. Published on MRC CTU at UCL website
Which people with metastatic prostate cancer benefit most from docetaxel?
Year(s) Of Engagement Activity 2023
URL https://www.mrcctu.ucl.ac.uk/media/2405/docetaxel-m1-meta-analysis-briefing-june23_v3.pdf
 
Description Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Relating to publication of: Vale CL et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol. 2023 Jul;24(7):783-797. doi: 10.1016/S1470-2045(23)00230-9. PMID: 37414011.
On publication there were a number of engagement activities including tweets from the Unit Twitter account, News story on Unit website (www.mrcctu.ucl.ac.uk) and www.STOPCAPM1.org website

http://www.stopcapm1.org/news/news-stories/2023/july/latest-stopcap-m1-results-published/
https://www.mrcctu.ucl.ac.uk/news/news-stories/2023/july/which-people-with-metastatic-prostate-cancer-benefit-most-from-upfront-docetaxel/
Year(s) Of Engagement Activity 2023
URL https://www.mrcctu.ucl.ac.uk/news/news-stories/2023/july/which-people-with-metastatic-prostate-cance...
 
Description metan: Stata package for aggregate-data MA 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Title: metan: a comprehensive update to the popular user-written meta-analysis package for Stata
Presenter: David Fisher
Cochrane Colloquium 2023; London
Poster presentation, Tuesday, 5 September 2023, 12:30 - 14:00
Year(s) Of Engagement Activity 2023
URL https://events.cochrane.org/colloquium-2023/schedule